 Bleomycin
"Bleomycin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
| Descriptor ID |
D001761
|
| MeSH Number(s) |
D09.400.420.110 D12.644.233.110
|
| Concept/Terms |
BLEO-cell- BLEO-cell
- BLEO cell
- BLEOcell
- cell pharm Brand of Bleomycin Sulfate
Bleolem- Bleolem
- Lemery Brand of Bleomycin Sulfate
Bleomicina- Bleomicina
- Almirall Brand of Bleomycin Sulfate
Bleomycinum Mack- Bleomycinum Mack
- Mack, Bleomycinum
- Mack Brand of Bleomycin Sulfate
Bléomycine Bellon- Bléomycine Bellon
- Bellon, Bléomycine
- Bellon Brand of Bleomycin Sulfate
Blenoxane- Blenoxane
- Bristol-Myers Squibb Brand of Bleomycin Sulfate
- Bristol Myers Squibb Brand of Bleomycin Sulfate
- Blanoxan
|
Below are MeSH descriptors whose meaning is more general than "Bleomycin".
Below are MeSH descriptors whose meaning is more specific than "Bleomycin".
This graph shows the total number of publications written about "Bleomycin" by people in this website by year, and whether "Bleomycin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 1 | 1 | | 1981 | 2 | 0 | 2 | | 1982 | 0 | 4 | 4 | | 1984 | 0 | 2 | 2 | | 1985 | 0 | 3 | 3 | | 1986 | 1 | 0 | 1 | | 1987 | 1 | 1 | 2 | | 1988 | 1 | 2 | 3 | | 1989 | 0 | 2 | 2 | | 1990 | 0 | 3 | 3 | | 1991 | 0 | 1 | 1 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 1 | 3 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 | | 2015 | 3 | 1 | 4 | | 2016 | 1 | 3 | 4 | | 2017 | 1 | 3 | 4 | | 2018 | 2 | 1 | 3 | | 2019 | 1 | 2 | 3 | | 2020 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Bleomycin" by people in Profiles.
-
Trendowski MR, Wheeler HE, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors. Clin Cancer Res. 2020 12 15; 26(24):6550-6558.
-
Guzy R. Fibroblast Growth Factor Inhibitors in Lung Fibrosis: Friends or Foes? Am J Respir Cell Mol Biol. 2020 09; 63(3):273-274.
-
Lee TH, Yeh CF, Lee YT, Shih YC, Chen YT, Hung CT, You MY, Wu PC, Shentu TP, Huang RT, Lin YS, Wu YF, Lin SJ, Lu FL, Tsao PN, Lin TH, Lo SC, Tseng YS, Wu WL, Chen CN, Wu CC, Lin SL, Sperling AI, Guzy RD, Fang Y, Yang KC. Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGFß signaling through TGFBR1 stabilization. Nat Commun. 2020 08 26; 11(1):4254.
-
Dorry SJ, Ansbro BO, Ornitz DM, Mutlu GM, Guzy RD. FGFR2 Is Required for AEC2 Homeostasis and Survival after Bleomycin-induced Lung Injury. Am J Respir Cell Mol Biol. 2020 05; 62(5):608-621.
-
Kim SJ, Cheresh P, Jablonski RP, Rachek L, Yeldandi A, Piseaux-Aillon R, Ciesielski MJ, Ridge K, Gottardi C, Lam AP, Pardo A, Selman M, Natarajan V, Kamp DW. Mitochondrial 8-oxoguanine DNA glycosylase mitigates alveolar epithelial cell PINK1 deficiency, mitochondrial DNA damage, apoptosis, and lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020 05 01; 318(5):L1084-L1096.
-
Huang LS, Sudhadevi T, Fu P, Punathil-Kannan PK, Ebenezer DL, Ramchandran R, Putherickal V, Cheresh P, Zhou G, Ha AW, Harijith A, Kamp DW, Natarajan V. Sphingosine Kinase 1/S1P Signaling Contributes to Pulmonary Fibrosis by Activating Hippo/YAP Pathway and Mitochondrial Reactive Oxygen Species in Lung Fibroblasts. Int J Mol Sci. 2020 Mar 17; 21(6).
-
Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 02; 61(2):298-308.
-
Suryadevara V, Huang L, Kim SJ, Cheresh P, Shaaya M, Bandela M, Fu P, Feghali-Bostwick C, Di Paolo G, Kamp DW, Natarajan V. Role of phospholipase D in bleomycin-induced mitochondrial reactive oxygen species generation, mitochondrial DNA damage, and pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019 08 01; 317(2):L175-L187.
-
Duan FF, Barron G, Meliton A, Mutlu GM, Dulin NO, Schuger L. P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-ß1, -ß2, and -ß3 Translation. Am J Respir Cell Mol Biol. 2019 02; 60(2):221-231.
-
Koo HY, El-Baz LM, House S, Cilvik SN, Dorry SJ, Shoukry NM, Salem ML, Hafez HS, Dulin NO, Ornitz DM, Guzy RD. Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. J Pathol. 2018 09; 246(1):54-66.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|